ArticleThe Pan African medical journal2025
Impact of immediate-release versus extended-release metformin on lipid profile and body measurements in Saudi patients with type 2 diabetes: a prospective cohort study.
Article in The Pan African medical journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: dyslipidemia and obesity frequently accompany type 2 diabetes, contributing to cardiovascular risk. Metformin, beyond its effects on glycemic control, can also influence lipid metabolism and weight. Immediate-release (IR) and extended-release (XR) metformin may have differential effects on lipid profile and anthropometric measures. The study aimed to compare the effects of metformin IR versus XR on lipid parameters and body measurements in patients with type 2 diabetes in Saudi Arabia. Methods: a prospective 6-month cohort study included 119 newly diagnosed type 2 diabetes patients (62 on metformin IR and 57 on metformin XR) at a Saudi hospital. Fasting lipid profile (T-Chol, TGs, HDL-C, and LDL-C) and body weight/BMI were measured at baseline and after 6 months of metformin treatment. Within-group changes and between-group differences were analysed. Results: both groups showed modest improvements in their lipid profile. Metformin XR use was associated with a greater reduction in total cholesterol (-7.8% vs. -5.8% with IR) and LDL-C (-8.7% vs. -5.7% with IR). After 6 months, mean LDL-C was significantly lower in the XR group (102.3 ± 37.5 mg/dL) compared to the IR group (116.9 ± 36.0 mg/dL, p=0.032). Triglyceride and HDL-C levels changed minimally and were similar between groups. Neither IR nor XR had a significant impact on body weight or BMI: both groups remained essentially weight-neutral (average weight change <1 kg over 6 months). Final mean BMI was 30.4 ± 5.9 kg/m Conclusion: metformin XR was associated with short-term benefits in reducing total and LDL cholesterol levels compared to IR, likely attributable to more stable plasma drug concentrations that enhance lipid metabolism. Both formulations exhibited similar effects on triglycerides, HDL cholesterol, and body weight, reaffirming metformin's overall neutral impact on weight. These findings suggest that metformin XR may offer a marginal reduction in cardiovascular risk through superior LDL cholesterol lowering, while preserving the weight-neutral profile characteristic of metformin therapy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.